ASX Company Announcements


The edited text of our announcements are sourced from the Australian Stock Exchange and are delayed by at least 20 minutes. Retrieving the edited text of a company announcement indicates your acceptance of the Conditions.

Cellmid does not take any responsibility in respect of any of the edited text sourced from the Australian Stock Exchange

 

 30/05/2018 5th Midkine Symposium Reinforces Clinical Potential for Cellmid's Biotechnology Assets

 29/05/2018

Change of Address

 02/05/2018

Cellmid to Commence Selling evolis into Chinese Market

24/04/2018

Cellmid Secures Bloomingdales USA Partnership for evolis

23/04/2018

Appendix 4C - Quarterly

10/04/2018

Cellmid Investor Presentation

09/04/2018

Cellmid Convening 5th Midkine Symposium in Munich

04/04/2018

Cellmid Signs Distribution Agreement for Fillerina

29/03/2018 

Change of Director's Interest Notice - Halasz

26/03/2018

Initial Director's Interest Notice - Eck

26/03/2018

Cellmid Appoints Dennis Eck Non-Executive Director

14/03/2018

Change of Director's Interest Notice - Halasz

21/02/2018

Confirmation of Release - CDY - Appendix 4D and Half Year Accounts

31/01/2018

Change of Director's Interest Notice - Halasz

25/01/2018

Appendix 4C

10/01/2018

Record $2M Quarterly Sales for Cellmid's FGF5 Inhibitors

09/01/2018

Cellmid Quarterly Operational update